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Background: We investigated patients with chronic obstructive pulmonary disease (COPD) to analyze patterns and
identify determinants of healthcare use, according to the severity of airflow obstruction. We used retrospective
cohort data from a combination of the 4th Korea National Health and Nutritional Examination Survey (KNHANES)
and Korean National Health Insurance (NHI) claims.
Methods: Demographic and medical claims data were retrospectively analyzed from the 4th KNHANES along with
NHI claims. Eligible patients were aged ≥40 years, who underwent complete pulmonary function tests (PFTs), and
had at least one inpatient or outpatient claim coded as COPD between January 1, 2007 and December 31, 2010.
Results: Among 6,663 eligible participants, 897 (13.5%) had airway obstruction. Self-reported physician-diagnosed
COPD comprised only 3%, and there were 870 undiagnosed COPD patients (97%). Self-reported physician-
diagnosed asthma made up 3.7%. Of the 897 respondents, 244 (27.2%) used COPD-related healthcare services. The
frequency of healthcare visits increased with increasing severity of airway obstruction. After a 3-year follow-up
period, 646 (74.2% of those initially undiagnosed) remained undiagnosed and only 224 (25.8%) were diagnosed and
treated for COPD. Only 27.5% of the 244 participants with airway obstruction who used COPD-related healthcare
underwent PFTs during the study period. The percentage of prescribed medications associated with COPD
increased in accordance with the severity of the COPD. Inhaled long-acting anticholinergics were prescribed for
10.9% of patients with moderate airway obstruction and for 52.4% of patients with severe obstruction. Inhaled
long-acting β-agonists combined with corticosteroids were prescribed for 50% of patients with severe airway
obstruction. Conversely, 44.6% of healthcare users were prescribed oral theophylline for COPD treatment, and 21.7%
were also prescribed an oral corticosteroid. The determinants of COPD-associated healthcare use in respondents
with obstructive lung disease were advanced age, severe airflow limitation, presence of comorbidities, and
self-reported physician diagnosis of COPD.
Conclusions: This study ascertained marked underdiagnosed COPD. Although the percentage of prescribed
medication used to treat COPD increased with the severity of the COPD, medications primarily prescribed such as
oral theophylline or oral corticosteroids are inappropriate for first-line COPD treatment.
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Chronic obstructive pulmonary disease (COPD) involves
progressive, irreversible airflow limitation resulting in
disabling respiratory symptoms and devastating comor-
bidities, all of which place an increasing burden on pub-
lic healthcare services [1-4]. COPD is the fourth leading
cause of death, but the World Health Organization pre-
dicts that it will move up to third by 2030. Furthermore,
COPD is often underdiagnosed and undertreated [5-9].
An understanding of the patterns of healthcare use is
fundamental for the establishment of a healthcare plan
geared towards the proper management and treatment
of COPD. Data about COPD-related healthcare, such as
hospital visits, the use of pulmonary function tests
(PFTs), and medications prescribed according to the se-
verity of symptoms, are lacking [10,11]. A retrospective
cohort was created from the combination of data from
the 4th Korea National Health and Nutritional Examin-
ation Survey (KNHANES) and Korean National Health
Insurance (NHI) claims. The aim of this study was to
analyze patterns and identify determinants of healthcare
use in COPD patients according to the severity of air-
flow obstruction.
Methods
Study population
Data for this study were obtained from KNHANES IV, in
which a stratified, multi-stage, clustered probability design
was used to select a representative sample of non-
institutionalized civilians from among the Korean popula-
tion. KNHANES IV data included information on demo-
graphics, smoking status, household income, education,
residential area, self-reported physician diagnoses (i.e.,
COPD, hypertension, ischemic heart disease, osteoporosis,
depression, and anemia), and PFTs. However, we inevitably
included self-reported physician diagnosis of asthma in our
study population because it is not possible to exclude
asthma patients using self-reported physician diagnosis cri-
teria. We describe the percentage of asthma patients in our
study in Table 1. Spirometry was performed by specially
trained technicians according to the 2005 American
Thoracic Society/European Respiratory Society recommen-
dations [12]. A total of 12,151 individuals from the
KNHANES IV data were older than 40 years of age; how-
ever, only 57.1% of these individuals (n = 6,934) underwent
complete PFTs. Informed consent was obtained from 96.1%
(n = 6,663) of the individuals. Their personal information
was successfully combined with records from the comput-
erized Korean NHI claims database between January 1,
2007 and December 31, 2010. The entire population of
South Korea has been provided with health coverage since
1989 by the Korean National Health Insurance System,
which has managed a computerized database for all med-
ical facilities in South Korea since 1998. The followingcodes from the Korean version of the International Classifi-
cation of Diseases, Tenth Revision (ICD-10) were used to
identify COPD-related healthcare use: simple and muco-
purulent chronic bronchitis (J41), simple chronic bronchitis
(J410), mucopurulent chronic bronchitis (J411), mixed sim-
ple and mucopurulent chronic bronchitis (J418), unspeci-
fied chronic bronchitis (J42), emphysema (J43), MacLeod
syndrome (J430), panlobular emphysema (J431), centrilob-
ular emphysema (J432), other emphysema (J438), emphy-
sema, unspecified (J439), other chronic obstructive
pulmonary disease (J44), chronic obstructive pulmonary
disease with acute lower respiratory infection (J440),
chronic obstructive pulmonary disease with acute exacerba-
tion, unspecified (J441), other specified chronic obstructive
pulmonary disease (J448), and chronic obstructive pulmon-
ary disease, unspecified (J449). Information on COPD-
related healthcare use from the NHI claims database con-
tained the frequency of healthcare visits, the number of
PFTs performed, and any prescribed medications. A total of
897 (13.4%) of 6,663 eligible individuals demonstrated an
obstructive airflow pattern and were included in the final
data analysis. Only 244 (27.2%) of these 897 patients used
the healthcare system, and they were assessed based on dis-
ease severity (Figure 1). The study protocol was approved
by the Public Institutional Review Board (PIRB 11-025-2).
Definition
COPD and severity of airway obstruction
Subjects ≥40 years of age with FEV1/FVC < 70% were diag-
nosed with COPD. The severity of airway obstruction was
classified as follows: mild (FEV1 ≥ 80% predicted), moderate
(50 ≤ FEV1 < 80% predicted), and severe (FEV1 < 50% pre-
dicted). Additionally, normal lung function was defined as
FEV1/FVC ≥ 70% and FVC ≥ 80% predicted. Restrictive
lung disease was defined as FEV1/FVC > 70% and FVC
< 80% predicted.
Users and non-users of COPD-related healthcare use
A user of COPD-related healthcare was defined as a person
with a first and second diagnosis of COPD who used any
kind of healthcare resource based on insurance claims data.
A non-user was defined as a person with a first and second
diagnosis of COPD during the follow-up period who did
not use healthcare resources.
Variables
Variables, such as the frequency of healthcare visits, per-
formance of PFTs, and the use of prescribed respiratory
medications, were used to investigate patterns of COPD-
related healthcare use (presented as the annual number
of visits per person). COPD-related healthcare visits
were defined as any kind of visit with first and second
diagnosis of COPD. Healthcare visits constituted visits
to outpatient clinics, inpatient clinics, intensive care
Table 1 Baseline characteristics of study population
Characteristics Normal Restrictive Obstructive Total
No. (%) No. (%) No. (%) No. (%)
4,895 (73.5) 871 (13.1) 897 (13.4) 6,663 (100.0)
Age group (yr)
40 ~ 49 1,923 (39.3) 171 (19.6) 86 (9.6) 2,180 (32.7)
50 ~ 59 1,455 (29.7) 222 (25.5) 175 (19.5) 1,852 (27.8)
60 ~ 70 1,028 (21.0) 259 (29.7) 309 (34.5) 1,596 (24.0)
70~ 489 (10.0) 219 (25.1) 327 (36.5) 1,035 (15.5)
Sex
Male 1,834 (37.5) 409 (47.0) 628 (70.0) 2,871 (43.1)
Female 3,061 (62.5) 462 (53.0) 269 (30.0) 3,792 (56.9)
Smoking status*
Never 3,184 (65.4) 505 (58.5) 292 (32.7) 3,981 (60.1)
Former 854 (17.5) 202 (23.4) 299 (33.5) 1,355 (20.5)
Current 830 (17.1) 156 (18.1) 301 (33.7) 1,287 (19.4)
Region of residence
Urban 3,514 (71.8) 607 (69.7) 532 (59.3) 4,653 (69.8)
Rural 1,381 (28.2) 264 (30.3) 365 (40.7) 2,010 (30.2)
Household income (quartile)*
1st quartile 962 (20.0) 251 (29.6) 347 (40.4) 1,560 (23.9)
2nd quartile 1,187 (24.7) 213 (25.1) 217 (25.3) 1,617 (24.8)
3rd quartile 1,204 (25.0) 211 (24.9) 152 (17.7) 1,567 (24.0)
4th quartile 1,456 (30.3) 174 (20.5) 142 (16.6) 1,772 (27.2)
Education*
≤Elementary school 1,663 (34.1) 370 (42.8) 474 (53.4) 2,507 (37.8)
Middle school 794 (16.3) 156 (18.1) 159 (17.9) 1,109 (16.7)
High school 1,480 (30.4) 204 (23.6) 155 (17.5) 1,839 (27.8)
≥College 938 (19.2) 134 (15.5) 100 (11.3) 1,172 (17.7)
No. of co-morbidities
0 3,125 (63.8) 429 (49.3) 477 (53.2) 4,031 (60.5)
1 1,231 (25.2) 291 (33.4) 288 (32.1) 1,810 (27.2)
2 430 (8.8) 118 (13.6) 111 (12.4) 659 (9.9)
≥3 109 (2.2) 33 (3.8) 21 (2.3) 163 (2.5)
No. of healthcare utilization
Yes 555 (11.3) 171 (19.6) 244 (27.2) 970 (14.6)
No 4,340 (88.7) 700 (80.4) 653 (72.8) 5,693 (85.4)
Self-reported physician diagnosis of asthma
Yes 107 (2.2%) 34 (3.9%) 33 (3.7%) 174 (2.6%)
No 4,788 (97.8%) 837 (96.1%) 864 (96.3%) 6489 (93.4%)
Self-reported physician diagnosis of COPD
Yes 28 (0.6) 7 (0.8) 27 (3.0) 62 (0.9)
No 4,867 (99.4) 864 (99.2) 870 (97.0) 6,601 (99.1)
*The sums of some data do not equal the total because of missing data; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 s
(liter); FVC = forced vital capacity (liter).
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Figure 1 Flow chart for selection of study participants. PFT = pulmonary function test; Normal = FEV1/FVC≥ 70% and FEV1 ≥ 80% predicted;
Restrictive = FEV1/FVC≥ 70% and FEV1 < 80% predicted; Obstructive = FEV1/FVC < 70%; Non-user = person who did not use healthcare resources at
all with first-listed and secondary diagnosis of COPD; User = person who used any kind of healthcare resource with first-listed and secondary
diagnosis of COPD.
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associated medication had >1 prescription for each drug
category per year during the follow-up period. COPD-
related medications were classified as follows: inhaled
short-acting β-agonists (SABA), inhaled short-acting
anticholinergics, inhaled long-acting anticholinergics
(LAMA), inhaled long-acting β-agonist combined with
corticosteroid (LABA/ICS), inhaled corticosteroid (ICS),
oral theophylline, and oral corticosteroid. Several vari-
ables were evaluated to identify the determinants of
COPD-related healthcare use in bivariate and multivari-
ate analyses. Variables included age, sex, smoking status,
residential area, household income, severity of airway
obstruction, presence of comorbidities, and self-reported
physician diagnosis of COPD.
Statistical analysis
Data were analyzed using SAS software, version 9.1 (SAS
Institute Inc., Cary, NC, USA). Baseline characteristics were
summarized using percentages to describe categorical vari-
ables, and compared using chi-square analyses. ANOVA
was used for analyzing variables associated with healthcare
use among subjects classified by severity of airflow obstruc-
tion. Determinants of healthcare use between healthcare
users and non-users were evaluated by logistic regression
analyses, including the following covariates: age, sex, smok-
ing status, residential area, household income, severity of
airway obstruction, and physician diagnosis of COPD. Oddsratios were reported with 95% confidential intervals. A
p value of <0.05 was regarded as statistically significant.
Results
Baseline characteristics of study population
Among 6,663 eligible respondents, 897 (13.5%) had airway
obstruction. Of these patients, 365 (40.7%) were classified
as having mild obstruction, 470 (52.4%) with moderate ob-
struction, and 62 (6.9%) with severe obstruction according
to performance on PFTs. COPD was more prevalent in
men. Self-reported physician-diagnosed COPD comprised
only 3%, and self-reported physician-diagnosed asthma
comprised 3.7% of the 897 subjects (Table 1).
Patterns of healthcare use by severity of airflow
obstruction
Of the 897 respondents, 244 (27.2%) used COPD-related
healthcare services. The frequency of healthcare visits
increased with increasing severity of airflow obstruction
(p < 0.01). Subjects with severe COPD visited healthcare fa-
cilities most frequently (Figure 2). Among those patients
with airflow limitation (N = 897), there were initially 870
(97%) undiagnosed COPD patients and 27 (3%) self-
reported physician-diagnosed COPD patients. After the
3-year follow-up period, 74.2% (N= 646) remained as un-
diagnosed COPD patients and only 25.8% (N = 224) were
diagnosed and treated as a COPD, among initially undiag-
nosed COPD patients (N = 870). Seven patients were
Figure 2 Percentage of COPD-related healthcare visits by severity of airway obstruction. Percentages of COPD related healthcare visits in
the mild, moderate, and severe airway obstruction cohort are presented on top of each bar of the graph. Total healthcare visits were divided into
outpatient clinic visits, inpatient clinic visits, and emergency department visits. a) COPD-related total healthcare visits, b) COPD-related outpatient
clinic visits, c) COPD-related inpatient clinic visits, d) COPD-related emergency department visits; mild = FEV1/FVC < 70% and FEV1 ≥ 80%
predicted; moderate = FEV1/FVC < 70% and 50 ≤ FEV1 < 80% predicted; severe = FEV1/FVC < 70% and FEV1 < 50% predicted; normal = FEV1/FVC
≥ 70% and FEV1 ≥ 80% predicted; restrictive = FEV1/FVC≥ 70% and FEV1 < 80% predicted.
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patients (N = 27). Only 27.5% of the 244 participants with
airway obstruction who used COPD-related healthcare
underwent PFTs during the study period (data not shown).
The percentage of patients undergoing spirometry in-
creased according to the severity of the airflow obstruction
(p = 0.03) (Figure 3; Table 2).
Patterns of prescribed medications according to the
severity of airflow obstruction
The percentage of prescribed medications associated
with COPD increased in accordance with the severity of
the COPD. Oral theophylline was prescribed as COPD
treatment for 44.6% of healthcare users, and 21.7% of
users were also prescribed an oral corticosteroid (data
not shown). The percentages of prescribed oral theo-
phylline were 33.8% for mild obstruction, 41.4% for
moderate obstruction, and 73.8% for severe obstruction
(Figure 4; Table 2). SABA was prescribed for 94.6% of
patients with mild airway obstruction, 82% withmoderate obstruction, and 61.9% with severe obstruction
(data not shown). LAMA was prescribed for 10.9% of
patients with moderate airway obstruction and for 52.4%
of patients with severe obstruction. LABA/ICS was pre-
scribed for 50% of patients with severe airway obstruc-
tion (Figure 4).
Bivariate and multivariate determinants of COPD-related
healthcare use
Bivariate and multivariate determinants influencing
COPD-related healthcare use are presented in Table 3.
Independent variables included in the multivariate logis-
tic analyses were age, sex, smoking status, household in-
come, residential area, severity of airway obstruction,
presence of comorbidities, and self-reported physician
diagnosis of COPD. The determinants of COPD-
associated healthcare use in participants with obstructive
lung disease were advanced age, severe airflow limita-
tion, presence of comorbidities, and self-reported phys-
ician diagnosis of COPD.
Figure 3 Performance in PFTs stratified by severity of airway
obstruction. Percentages of each PFT performance in the mild,
moderate, and severe airway obstruction cohort are presented on
top of each bar in the graph.
Table 2 Patterns of healthcare visits, PFTs, and prescribed me
Mild
No. (%)
74 (30.3)
Healthcare visit (frequency/person/year)*
Total 2.014 ± 0.323
Outpatient clinic 1.895 ± 0.325
Inpatient clinic 0.118 ± 0.051
ICU 0.025 ± 0.020
ED 0.009 ± 0.007
PFT (frequency/person/year)* 0.109 ± 0.032
Medications (frequency/person/year)*
SABA 0.050 ± 0.026
SAMA 0.036 ± 0.023
LAMA 0.178 ± 0.163
LABA+ICS 0.054 ± 0.046
ICS 0.050 ± 0.045
Oral theophylline 0.484 ± 0.121
Oral corticosteroid 0.143 ± 0.081
*=mean ± standard error; ICU = intensive care unit; ED = emergency department; PF
SAMA = inhaled short-acting anticholinergic; LAMA = inhaled long-acting anticholine
ICS = inhaled corticosteroid.
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In this study, patterns of healthcare use in subjects with
COPD were assessed based on representative, nation-
wide epidemiological cohort data combined with Korean
NHI claims data. The NHI system provides an exact and
reliable computerized database for all healthcare service
use for the entire population of South Korea. A few epi-
demiological reports on COPD-related healthcare use
exist in the literature [10,13-16]; however, reports on the
association between healthcare use patterns and COPD
severity are scarce. Our study also identified a total
27.2% (N = 244) COPD-related healthcare use rate. We
observed an increase in use according to disease severity,
which was a strong predictor of future healthcare use.
However, PFTs were performed in only 27.5% of patients
with COPD. Medications prescribed for COPD in Korea
were mainly oral theophylline (44.7%) and oral cortico-
steroids (21.7%), regardless of the disease severity. The
major determinants for COPD-related healthcare use
were advanced age, disease severity, presence of comor-
bidities, and physician diagnosis of COPD. These factors
should be considered in health plans and in disease
management programs for COPD.
The present study showed that total prevalence of COPD
based on PFTs was 13.4%. The prevalence of COPD in
other countries varies from 7.8% to 19.7% [17-19]. In our
study, the percentage of self-reported physician-diagnosed
COPD was 3% (N= 27) and the percentage of PFT-based
undiagnosed airway obstruction was 13.1% (N = 870).dications according to severity of airflow obstruction
Moderate Severe
No. (%) No. (%)
128 (52.5) 42 (17.2) P value
3.675 ± 0.473 5.764 ± 0.783 <0.001
3.594 ± 0.472 5.516 ± 0.732 <0.001
0.082 ± 0.021 0.248 ± 0.114 0.091
0.005 ± 0.004 0.039 ± 0.024 0.219
0.023 ± 0.010 0.071 ± 0.049 0.124
0.168 ± 0.025 0.263 ± 0.059 0.031
0.287 ± 0.135 0.957 ± 0.290 0.003
0.036 ± 0.015 0.200 ± 0.104 0.012
0.213 ± 0.080 1.940 ± 0.492 <0.001
0.408 ± 0.137 1.280 ± 0.395 <0.001
0.032 ± 0.014 0.194 ± 0.107 0.051
1.156 ± 0.254 3.162 ± 0.571 <0.001
0.390 ± 0.116 1.422 ± 0.451 <0.001
T = pulmonary function test; SABA = inhaled short-acting β agonist;
rgic; LABA+ICS = inhaled long-acting β-agonist combined with corticosteroid;
Figure 4 Percentages of medications prescribed, classified by
severity of airway obstruction. Percentages of prescribed medications
in the mild, moderate, and severe airway obstruction cohort are
presented on top of each bar in the graph. LAMA= inhaled long-acting
anticholinergic; ICS = inhaled corticosteroid; LABA= inhaled long-acting
β-agonist; OCS = oral corticosteroid.
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published by Coultas et al. [20], in which the percentage of
doctor-diagnosed COPD was 3.1% (N = 179) and of undiag-
nosed airflow obstruction was 12.0% (N = 688). Other na-
tional data reveal that <6% of the adult population has been
told by a healthcare provider that they have COPD
[4,6,7,9]. The reasons for underdiagnosis of COPD include
low usage of PFTs [21,22], lack of awareness of COPD, poor
physician adherence to guidelines [23], and lack of educa-
tional programs on COPD. Asymptomatic COPD patients
do not tend to use healthcare services. Most primary care
physicians diagnosed COPD based on patients’ symptoms
and smoking history [21]. Objective diagnosis using PFTs
tends to produce higher prevalence estimates than patient-
reported diagnosis. The underdiagnosis of COPD is likely
to result in substantial morbidity and mortality.
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) recommends that PFTs be used for the
clinical diagnosis of COPD to avoid underdiagnosis, and
to ensure proper evaluation of the severity of the airflow
obstruction [4]. Other studies also reported that PFTs
were underused in detecting patients with COPD and
confirming the diagnosis of COPD [24,25]. Dyspnea,
coughing, wheezing, and smoking history are not spe-
cific to COPD [24]. PFTs can detect asymptomatic
COPD early, which allows for risk factors to be modified
(i.e., smoking cessation) [25]. Early detection of COPD is
important in Korean men because of that country’s high
male smoking rate relative to the female smoking rate(60.6% vs. 5.2%, respectively) [26]. Han et al. revealed
that only 32% of COPD patients in the United States
had PFTs performed within 2 years before, or 6 months
after, diagnosis [27]. Our study suggested that the low
rate of PFTs performed (27.5%) might be associated with
the underdiagnosis of COPD in Korea.
Interestingly, the percentages of prescribed oral theophyl-
line (44.6%) and oral corticosteroids (21.7%) were high re-
gardless of the severity of airflow obstruction in our study
(data not shown). The high prescribing rate of oral theo-
phylline may be associated with patients’ preference for oral
medications in Korea. The low prescribing rate of LAMA
and LABA/ICS may be related to underdiagnosis of COPD.
The GOLD guidelines clearly outline which classes of
COPD medications should be prescribed according to dis-
ease severity. A few reports demonstrate that COPD treat-
ment guidelines reduce healthcare use and mortality [28].
Nevertheless, physician adherence to prescribing guidelines
and patient adherence to drug therapy remain poor [10,29].
The COPD Resource Network Needs Assessment Survey
reported that 54% of primary physicians and 94% of pulmo-
nologists under-prescribed recommended pharmacological
treatments despite acknowledging awareness of the current
COPD treatment guidelines [30]. Park et al. showed that
56.7% of primary care physicians in Korea knew about the
GOLD guidelines and 61.8% had spirometry equipment.
However, PFTs were often underused because of problems
with spirometry equipment, refusal by patients, and un-
awareness of the importance of screening patients for
COPD. Common respiratory medications prescribed for
stable COPD included oral theophylline (24.9%), inhaled
anticholinergics (22.1%), oral β2-agonists (17.1%), and in-
haled β2 agonists (15.7%), which was consistent with our
results [31].
Our study revealed that the severity of the airflow ob-
struction was one of the major determinants of COPD-
related healthcare use. Some authors have suggested that
comorbidities or symptoms were more relevant determi-
nants than the severity of the airway obstruction in de-
termining healthcare use [16,32-34]. Other authors
showed that the severity of COPD was strongly corre-
lated with healthcare use [29,35]. In our study, subjects
with moderate and severe airway obstruction used
healthcare services more frequently than patients with
mild obstruction. Additionally, in our study, age and co-
morbidities were also identified as determinants of
COPD-related healthcare use [32]. Unlike other studies,
household income [15] and smoking status [16] were
not related to healthcare use. In this study, self-reported
physician-diagnosed COPD was also a major determin-
ant of healthcare use. Lack of knowledge about COPD
may affect the use of healthcare, but further study is
needed. However, we did not include acute exacerbation
events with the classical criteria of acute exacerbation.
Table 3 Bivariate and multivariate determinants of COPD-related healthcare use
Variables COPD-related healthcare utilization
User Non-user
No. (%) No. (%)
244 (27.2) 653 (72.8) OR 95% CI P value
Age (yr)
40 ~ 59 50 (19.2) 211 (80.8) 1.00
≥60 194 (30.5) 442 (69.5) 1.56 1.03 - 2.36 0.04
Sex
Female 74 (27.5) 195 (72.5) 1.00
Male 170 (27.1) 458 (72.9) 1.13 0.71 - 1.77 0.61
Smoking status
Never 75 (25.7) 217 (74.3) 1.00
Former 82 (27.4) 217 (72.6) 1.04 0.63 - 1.70 0.89
Current § 87 (28.9) 214 (71.1) 1.32 0.82 - 2.13 0.26
Residential area
Urban 138 (25.9) 394 (74.1) 1.00
Rural 106 (29.0) 259 (71.0) 1.07 0.78 - 1.48 0.68
Household income
≥Lower quartile 129 (23.5) 421 (76.6) 1.00
<Lower quartile 115 (33.1) 232 (66.9) 1.32 0.94 - 1.85 0.10
Severity of airway obstruction
Mild 74 (20.3) 291 (79.7) 1.00
Moderate 128 (27.2) 342 (72.8) 1.54 1.10 - 2.15 0.01
Severe¶ 42 (67.7) 20 (32.3) 6.68 3.60 - 12.38 <0.01
No. of co-morbidities
0 107 (22.4) 370 (77.6) 1.00
≥1 137 (32.6) 283 (67.4) 1.44 1.03 - 2.01 0.03
Self-reported physician diagnosis of COPD
No 224 (25.8) 646 (74.3) 1.00
Yes 20 (74.1) 7 (25.9) 5.30 2.08 - 13.54 <0.01
OR = odds ratio; CI = confidence interval. § Comparison with never smoker; ¶ Comparison with mild airway obstruction.
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acute event characterized by a worsening of the patient’s
respiratory symptoms that is beyond normal day-to-day
variations, and leads to a change in medication. In most
studies concerned with acute exacerbation of COPD,
moderate to severe exacerbation of COPD is defined by
an emergency room visit or admission due to COPD.
We analyzed data regarding COPD-related admissions
to hospital and visits to emergency departments, which
can be considered as involving moderate to severe ex-
acerbation of COPD.
There are several limitations to our study. First, the
follow-up period was only 1–3 years. Second, results
from this study cannot be generalized to the entire
Korean population over 40 years of age. Participants in
this study might have been relatively healthy, whilesedentary patients with severe airway obstruction might
not have been included in our study. Thus, we cannot
entirely rule out selection bias. In addition, healthcare
users comprised a small sample size. Further studies
need a larger, nationwide sample with a much longer
follow-up period. Third, eligible participants were se-
lected using a fixed FEV1/FVC ratio, and airflow ob-
struction was determined without consideration of the
decrease in pulmonary function that occurs with age.
COPD among the elderly in our study seemed over-
represented [36]. Furthermore, lung function data from
this study were based on pre-bronchodilator PFTs, and
the inadvertent inclusion of asthma patients might have
skewed the results. In addition, in the survey question-
naire, we had questions regarding self-reported physician
diagnosis of asthma. In doing so, we were trying to
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using self-reported physician diagnosis criteria. It is a
limitation of nationwide surveys, and it is not possible to
differentiate COPD patients from asthma patients in the
KNHANES study. We could not exclude from this study
population asthma patients older than 40 years of age
who had airflow limitation. As a result, we analyzed pat-
terns and determinants of healthcare use in patients
with airway obstruction, which might have included
cases with COPD or bronchial asthma. We tried to clar-
ify data from COPD-related ICD-10 codes in NHI claims
during the 3-year follow-up period. Therefore, the num-
ber of patients who did not use healthcare resources
might have included cases with COPD or asthma.
Fourth, identification of patients based on insurance
claims data also relies on the correct use and input of
codes into the computerized insurance database. It
would have been useful to have data regarding non-
pharmacological interventions such as smoking cessa-
tion, physical activity, rehabilitation, and vaccination.
Unfortunately, we could not extract information about
non-pharmacological interventions using COPD-related
claims codes from the NHI claims data, because non-
pharmacological interventions are not covered and reim-
bursed by the NHI system in Korea. This is also a limita-
tion. Last, we could not analyze data about respiratory
symptoms because major questions about such symp-
toms were not included in the survey questionnaire. We
accept that the absence of analysis regarding respiratory
symptoms is a flaw. These factors could influence major
determinants of healthcare use [16]. There is still debate
about the use of spirometry vs. symptom questionnaires
[37] in the screening and diagnosis of COPD. Future
studies should analyze the severity of airflow obstruction
with well-established lung function questionnaires.
Conclusions
Among patients with COPD, 27.2% used COPD-related
healthcare services. Only 27.5% of the 244 participants
with airway obstruction who used COPD-related health-
care underwent PFTs. The percentage of prescribed
medications associated with COPD increased in accord-
ance with the severity of the COPD. However, oral theo-
phylline and oral corticosteroids were mainly prescribed.
The determinants of COPD-associated healthcare use in
subjects with obstructive lung disease were advanced
age, severe airflow limitation, presence of comorbidities,
and self-reported physician diagnosis of COPD.
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